News | August 16, 2025
Cohance Lifesciences reports 13% revenue growth in Q1 FY26
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Rivaroxaban is used to treat venous thromboembolism
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
This strategic investment strengthens Cohance's integrated oligonucleotide platform
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Subscribe To Our Newsletter & Stay Updated
